ipamorelin clinical trial results CJC-1295 + Before & After Ipamorelin UK: Research Status, Testing
Description
Primary handling editor: Christoph Schmitt
69 demonstrated the role of MOF nanoparticles in delivering antisense oligonucleotides, which target PD-L1 to increase immune cell activity and inhibit tumor growth
[DOI] [PMC free article] [PubMed] [Google Scholar] 59.Guney Varal I., Dogan P., Gorukmez O., Dorum S., Akdag A
Accordingly, a phase 3 clinical trial is ongoing (ClinicalTrials.gov Identifier: NCT05946941)
